on ABIVAX (EPA:ABVX)
Abivax Joins CAC Mid 60 and SBF 120 Indices
On September 12, 2025, Abivax, a clinical-stage biotechnology company, announced its inclusion in the CAC Mid 60 and SBF 120 indices following the annual review by Euronext Paris. This change will take effect on September 19, 2025, after market close. The indices represent mid-sized and major securities on the Euronext Paris exchange, respectively.
The inclusion is expected to enhance Abivax's visibility, making its shares more accessible to institutional investors and funds linking them to indices. Marc de Garidel, CEO of Abivax, expressed that this addition is a recognition of market confidence in the company's strategic visions and their execution. It aligns with Abivax's commitment to providing innovative therapies for chronic inflammatory diseases and generating long-term shareholder value.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news